Idera Pharmaceuticals, Inc. (IDRA): M&A News

IDRA – BioCryst Pharma terminates merger agreement with Idera Pharma.


Key Facts Surrounding This News Item


  • IDRA had a POWR Rating of D (Sell) coming into today.
  • IDRA was 4.15% above its 10-Day Moving Average coming into today.
  • IDRA was -6.76% below its 20-Day Moving Average coming into today.
  • IDRA was -18.66% below its 50-Day Moving Average coming into today.
  • IDRA was -21.92% below its 100-Day Moving Average coming into today.
  • IDRA was -28.86% below its 200-Day Moving Average coming into today.
  • IDRA had returned -34.60% year-to-date leading up to today’s news, versus a +5.02% return from the benchmark S&P 500 during the same period.

More Info About Idera Pharmaceuticals, Inc. (IDRA)


Idera Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. The company was founded in 1989 and is based in Cambridge, Massachusetts. View our full IDRA ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

IDRA at a Glance

IDRA Current POWR Rating™
Overall POWR Rating™
IDRA Current Price $0.99 1.98%
More IDRA Ratings, Data, and News

IDRA Price Reaction

The day of this event (Jul. 10, 2018)
IDRA Closing Price$1.37 0.72%
IDRA Volume1,185,700
29.71% from avg
Leading up to this event
IDRA 1-mo returnN/A%
After this event
IDRA 1-day return26.61%
IDRA 3-day return36.63%

IDRA Price Chart



More Idera Pharmaceuticals, Inc. (IDRA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All IDRA News
Page generated in 0.9381 seconds.